Diagnostic criteria for dementia with Lewy bodies: Updates and future directions

Masahito Yamada; Junji Komatsu; Keiko Nakamura; Kenji Sakai; Miharu Samuraki-Yokohama; Kenichi Nakajima; Mitsuhiro Yoshita

추천

검색

자료유형: 학술저널

저자정보: Masahito Yamada (Kanazawa University Graduate School of Medical Sciences Kanazawa Japan) Junji Komatsu (Kanazawa University Graduate School of Medical Sciences) Keiko Nakamura (Kanazawa University Graduate School of Medical Sciences) Kenji Sakai (Kanazawa University Graduate School of Medical Sciences) Miharu Samuraki-Yokohama (Kanazawa University Graduate School of Medical Sciences) Kenichi Nakajima (Kanazawa University Graduate School of Medical Sciences) Mitsuhiro Yoshita (Kanazawa University Graduate School of Medical Sciences)

저널정보: 대한파킨슨병및이상운동질환학회 Journal Of Movement Disorders Journal Of Movement Disorders Vol.13 No.1

발행연도: 2020.1

수록면: 1 - 10 (10page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology.

#α-synuclein #Clinical practice guideline #Dementia #Lewy body #Myocardial scintigraphy

참고문헌 (64)

참고문헌 신청

Outeiro TF / 2019 / Dementia with Lewy bodies: an update and outlook / Mol Neurodegener 14:5

Masuda-Suzukake M / 2014 / Pathological alpha-synuclein propagates through neural networks / Acta Neuropathol Commun 2:88

Uchihara T / 2016 / Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies / Acta Neuropathol 131:49~73

Kim S / 2019 / Transneuronal propagation of pathologic α-Synuclein from the gut to the brain models Parkinson’s disease / Neuron 103:627~641

Wakisaka Y / 2003 / Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study / Acta Neuropathol 106:374~382

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Masahito Yamada

소속기관 Kanazawa University Graduate School of Medical Sciences Kanazawa Japan

주요연구분야 의약학 > 임상의학 > 신경과학

논문수 1 이용수 0

Junji Komatsu